A gadolinium-complex-based theranostic prodrug for in vivo tumour-targeted magnetic resonance imaging and therapy.
Here we report a target-specific theranostic prodrug (1a) containing Gd-DOTA, biotin, and camptothecin (CPT) along with a disulfide self-immolative linker. This prodrug exhibits selective targeting towards tumour cells and tissues, stimuli-responsive controlled release, enhanced anticancer efficacy, and accurate diagnosis and real-time monitoring via contrast-enhanced magnetic resonance imaging (MRI).